Mr Paul Hopper
Paul Hopper has more than 20 years’ experience in international public company markets, with a focus on start-up and rapid growth companies where he has served as either Chairman, Non-Executive Director or CEO. His focus has been primarily in the life-sciences sector, steering around fourteen public companies in the US, Australia, and Asia.
Paul is an advisor at the Los Angeles-based Cappello Group where he is Head of the Life Sciences and Biotechnology Group responsible for mergers and acquisitions and capital raisings focusing on the biotechnology and life sciences sectors.
He is a Non-Executive Director of Prescient Therapeutics Ltd, the former Chairman of Viralytics Ltd (sold to Merck in 2018 for $500m) and founder of Pathway Oncology.
Managing Director & Chief Executive Officer
Ms Chong most previously was a Senior Clinical Program Lead at Genentech, a member of the Roche family, in the head office in San Francisco. She has over 17 years of experience in leading clinical and department development in oncology. Most recently, she was the clinical operations program lead for the approved MEK inhibitor in cell-signalling targeted therapy, cobimetinib/Cotellic.
Prior to Genentech, Ms Chong was one of the clinical operation head at Exelixis, in development of 14 compounds and molecules. She has also been a member of the clinical operation department at GSK and PPD.
Leslie believes that early development and research innovation has the ability to bring transformative medicine to patients in need.
Mr Charles Walker
Having spent around 20 years in the industry, Imugene NED Charles Walker is best known for his most recent role as CEO of Imugene Ltd, and also CEO, and earlier CFO, of Alchemia Limited. His three year tenure at Alchemia saw the launch and growth of sales of Alchemia’s first marketed product fondaparinux, the initiation of Phase III and Phase II clinical trials of Alchemia’s anti-cancer drug candidate HA-Irinotecan, the establishment of a partnership with Astra Zeneca AB and the establishment of a collaboration with Merck-Serono SA.
Prior to Alchemia, Charlie spent over a decade in corporate finance advising a variety of international technology companies and executing over 40 successful transactions including IPOs, M&A agreements and capital raisings.
Mr Walker possesses a deep understanding of life sciences financing and commercialisation, and his experience covers strategy, licensing, partnering, investor outreach and clinical trials. His education includes an MBA at Warwick Business School and a Pharmacology degree from the University of Bristol in the UK.
Dr Axel Hoos
Dr. Axel Hoos is Senior Vice President and Therapeutic Area Head, Oncology R&D at GlaxoSmithKline Pharmaceuticals (GSK). As leader of the Oncology TA he oversees both its discovery and development functions and builds the Oncology portfolio of GSK across several modalities including antibodies, small molecules, bispecific molecules and cell & gene therapies. The TA’s scientific focus is on Immuno-Oncology, Epigenetics and Cell Therapy.
Dr. Hoos also serves on the Scientific Advisory Board of the HIV Cure Center, a co-venture of GSK and the University of North Carolina at Chapel Hill.
Dr. Hoos further serves as Executive Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, Co-Chairman of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). He further is a Scientific Advisory Group member at the Parker Institute for Cancer Immunotherapy (PICI), and Industry Co-Chair of the Partnership for Acceleration Cancer Therapies (PACT) of the U.S. Cancer Moonshot. His efforts in Medicines Development and Global Health focus on novel and transformational therapies for life-threatening diseases, scientific and procedural innovation, and broad collaboration across multiple constituents to solve complex health problems. Through his leadership a new paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology.
Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy in Immuno-Oncology. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company.
Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich, Germany and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.
Dr Mark Marino
Chief Medical Officer
Dr Marino leads the Company’s global clinical development, regulatory and medical monitoring activities. Dr Marino brings deep experience to the Company, having held senior level clinical development/leadership & CMO positions at top tier pharmaceutical companies, including Daiichi-Sankyo, Hoffman-La Roche AG, and Novartis Pharmaceuticals Corp. In his previous roles, Dr Marino headed teams in oncology, cardiology, endocrinology and rare-diseases where he was responsible for clinical development through to commercialization and life cycle management. He also successfully engaged key stakeholders including the scientific community, scientific boards, advocacy groups and key opinion leaders. Prior to his move into the pharmaceutical industry, Dr Marino spent 7 years with the US Military’s Walter Reed Army Institute of Research, the Walter Reed Army Medical Center and the Uniformed Services University of the Health Sciences.
Dr Marino holds a Medical Doctor degree from the Albert Einstein College of Medicine and a Bachelor of Science in Chemistry from the United States Military Academy.
Professor Ursula Wiedermann
Chief Scientific Officer
Professor Wiedermann is Professor of Vaccinology and Head of the Institute of Specific Prophylaxis and Tropical Medicine of the Medical University Vienna. Currently she also has an appointment as Visiting Professor at the University in Göteborg, Sweden. She has more than 100 peer-reviewed publications and is frequently performing presentations at national and international conferences. Professor Wiedermann was the Principal Investigator for the preclinical development of HER-Vaxx and together with Prof. Zielinski´s Division the Phase I clinical trial of HER-Vaxx in metastatic breast cancer patients was performed. Furthermore she has led the design of the Phase II study for gastric cancer due to commence in 2015.
Professor Wiedermann had studied Medicine in Vienna, Austria. Between 1990-1995 she entered a PhD-program in Sweden at the Institute of Clinical Immunology at the University Gothenburg, focusing her research on mucosal immunity and vaccination. Back in Vienna she continued her research career at the University of Vienna concentrating on mucosal vaccination against allergic diseases. After her habilitation (venia docendi) in 1999 she founded the research group “Mucosal Immunity and Vaccination”. In 2001 she finished her medical training as specialist for “Immunology” and “Specific Prophylaxis and Tropical Hygiene”. At the Institute of Specific Prophylaxis and Tropical Medicine she enlarged her research areas to vaccine development against infectious diseases and tumours, and focused on clinical vaccine trials to study immune responsiveness and immune failures upon vaccination. In 2004 she became Head of the Institute of Specific Prophylaxis and Tropical Medicine of the Medical University Vienna and in 2006 she was assigned Professor for Vaccinology at the Medical University Vienna. She is a member of the Supreme Board of Health and the Chairman of the National Committee of Immunization Practice of the Austrian Ministry of Health. Since 2009 she is Speaker of the newly founded Centre for Geographic Medicine at the Medical University Vienna.
Dr Nick Ede
Chief Technology Officer
Dr Ede has a record of successfully evolving research concepts to commercial products and processes. He has over 25 years experience in drug discovery and international business development gained at Chiron Corporation - now Novartis (VP Chemistry), EqiTX Ltd (COO), Mimotopes Pty Ltd (CEO), Adistem Ltd (CEO) and Consegna Ltd (CTO). He has established joint ventures and partnerships with some of the leading pharmaceutical and biotechnology companies in the world, including a global peptide supply alliance with the world's 4th largest biotechnology company Genzyme Inc, Invitrogen Inc (exclusive peptide partnership), drug discovery partnerships with GSK, J&J and Novartis, and the Broad Institute (a joint venture of Harvard and MIT) and Infinity Pharmaceuticals (NASDAQ: INFI) where his combinatorial chemistry platform technology was installed and utilised for drug discovery projects. INFI chemists made over 260,000 structurally complex compounds on his platform, which helped raise >$60M in funding spread over three chemistry deals (Amgen, J&J, Novartis). Additionally, screening these compounds initiated an oncology program, which was subsequently partnered (Novartis) and brought in an additional $30M. He holds a PhD from Monash University and Grad. Cert. in Innovation from Melbourne Business School, and has published over 50 scientific papers and patents.
Dr Anthony Good
Vice President Clinical Research
Dr Good was previously Clinical Program Director at Imugene Limited (ASX:IMU) where he was responsible for constructing the protocol and leading the execution of Imugene’s multi-national Phase 1b/2 clinical trial of HER-Vaxx, Imugene's proprietary and novel B-cell vaccine for the treatment of HER2 overexpressing gastric cancer.
Dr Good’s was also Clinical Program Director at Kazia Limited (ASX:KZA) where he was responsible for leading Kazia’s multi-national Phase 2 clinical development program of the brain penetrant PI3K/mTOR inhibitor, GDC-0084, for treatment of the debilitating brain cancer glioblastoma multiforme. During his time at Kazia, Dr Good was also responsible for presenting the GDC-0084 clinical development program for review and approval by the US FDA.
Dr Good has held numerous senior clinical research roles including Clinical Program Manager, Pfizer Global Research and Development, Sandwich, UK where he contributed to the development of Viagra, Revatio, Lipitor, Fablyn and Somavert. He has over 20 years’ experience in clinical research including extensive experience across all phases of clinical development and across a broad range of therapeutic areas including immuno-oncology, neuro-oncology, central nervous system, and cardiovascular.
Dr Good holds a BSc (Hons) and a PhD in neuroscience from the University of New South Wales.